Medication info
Pregabalin 150 mg Capsule

Pregabalin 150 mg Capsule

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
IYON Pharmaceutical Co., Ltd.
Appearance
White or light yellowish-white powder in a hard capsule with a white upper and lower part.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201600856 · Approved 2016.02.15 · Insurance code 658603430

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin divided into 2 doses, orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. (Refer to section 5. Patients with Renal Impairment.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to section 4. Discontinuation of Treatment.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Dosing regimen | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: Supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12 ~17 years: Administration is not recommended because sufficient safety and efficacy data are not available.

Ingredients

Manufacturer
IYON Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for partial seizures in epilepsy patients, whether they have secondary generalization or not. Additionally, it helps alleviate symptoms in patients with fibromyalgia. It is widely used for the treatment of various neurological disorders.

How to take

Adult dose

Administer the total daily dose of pregabalin divided into 2 doses, orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. (Refer to section 5. Patients with Renal Impairment.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to section 4. Discontinuation of Treatment.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Dosing regimen | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: Supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12 ~17 years: Administration is not recommended because sufficient safety and efficacy data are not available.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so it is important to inform healthcare providers immediately if any signs of depression or mood changes appear during treatment. Patients allergic to any ingredients contained in this medication or with specific hereditary conditions such as lactose intolerance should not take it. Diabetes patients should be cautious as dose adjustments of blood sugar control medications may be required due to weight gain. If any signs of hypersensitivity, such as angioedema, occur, the medication should be stopped immediately. Elderly patients should take care due to the risks of dizziness or drowsiness leading to injuries. Blurred vision or changes in vision may occur, and if symptoms arise, consultation with healthcare providers is necessary. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, or anxiety, so it should be tapered off according to a physician's instructions. There is a risk of drug abuse, so patients with a history of substance abuse should take this medication with special caution and report any unusual behavior immediately. Patients with decreased kidney function may need dose adjustments. Patients with heart conditions should be cautious when taking this medication, and the risk of central nervous system depression increases when used with opioid analgesics. Pregnant women should not take this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Breastfeeding women should discuss with healthcare providers about stopping breastfeeding or the medication as it may be transmitted through breast milk. Caution is necessary when driving or operating machinery due to possible dizziness and drowsiness. In case of overdose, symptoms may include confusion, drowsiness, and depression, necessitating immediate medical attention. This medication should be stored out of reach of children, and it is safest not to transfer it to another container.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 183 more
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinopharyngitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual sensation disorder
  • anxiety
  • mood swings
  • emotional lability
  • elevated mood
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • coordination disorders
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory deficits
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • language disorders
  • tonic-clonic seizures
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing disorder
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • tachyarrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal hemorrhage
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • hives
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • sensation of intoxication
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusion
  • depression
  • agitation
  • restlessness
  • seizure exacerbation
  • sleep disorders
  • skin disorders
  • bloody stools
  • increased BUN
  • speech disorders
  • tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is susceptible to air and humidity, so it should be stored in a tightly sealed container. It is recommended to maintain the storage temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

White or light yellowish-white powder in a hard capsule with a white upper and lower part.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.